{"id":"lasofoxifene-in-combination-with-abemaciclib","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL6067998","moleculeType":"Small molecule","molecularWeight":"563.65"},"_fixedAt":"2026-03-30T11:48:19.411324","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lasofoxifene acts as an estrogen receptor antagonist in breast tissue, blocking growth signals driven by estrogen in hormone receptor-positive (HR+) breast cancer. Abemaciclib inhibits cyclin-dependent kinases 4 and 6, preventing the G1/S cell cycle checkpoint and halting cancer cell proliferation. Together, they provide dual inhibition of estrogen-driven growth and cell cycle progression.","oneSentence":"Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:18.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women)"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05696626","phase":"PHASE3","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"RECRUITING","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT04432454","phase":"PHASE2","title":"Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"COMPLETED","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2020-09-29","conditions":"Metastatic Breast Cancer","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lasofoxifene in combination with abemaciclib","genericName":"Lasofoxifene in combination with abemaciclib","companyName":"Sermonix Pharmaceuticals Inc.","companyId":"sermonix-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells. Used for Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}